Nautilus

Biotech & Life Sciences · San Carlos, United States · Founded 2016 · Public via SPAC 2021

Nautilus Biotechnology operates in the biotechnology sector, focusing on proteomics, which is the large-scale study of proteins. The company has developed an advanced platform designed to accelerate the drug development process by providing researchers with deep insights into the roles of drug targets in health and disease. This platform aims to make it easier to prioritize drug targets with high potential for clinical success, thereby reducing inefficiencies and costs associated with traditional drug discovery methods. Nautilus Biotechnology serves pharmaceutical companies, research institutions, and biotech firms, offering them a tool to enhance their research capabilities and improve clinical outcomes. The business model is primarily B2B (business-to-business), generating revenue through the sale of its proteomics platform and related services. By unlocking the proteome, Nautilus aims to fuel breakthroughs in basic biology, medicine, and biotechnology, ultimately impacting global health positively. Keywords: proteomics, drug discovery, biotechnology, clinical success, pharmaceutical, research, platform, health, innovation, efficiency.

Valuation $0–100M

Revenue <$1M

Headcount 100–500

Total funding $100–500M

Power Law Unicorn$1–10B valuation tier

Investors

15 investors on Nautilus's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 8 investors entered at this stage

Defy Partners

Bolt Ventures

Bezos Expeditions

Madrona Venture Group

Series B+ 7 investors entered at this stage

Casdin Capital

OrbiMed

Franklin Templeton Investments

Bain Capital Life Sciences

RA Capital Management

Ally Bridge Group

Arya Sciences Acquisition III

Global footprint

Where Nautilus has talent and traffic

Workforce by country

3 countries with
team presence

🇺🇸 United States98.3%

🇬🇧 United Kingdom0.9%

🇮🇳 India0.9%

3 countries shown

Web traffic by country

18K monthly visits
across markets

🇺🇸 United States42.8%

🇮🇳 India37.2%

🇨🇦 Canada6.7%

🇯🇵 Japan5%

🇬🇧 United Kingdom4.4%

Top 5 markets shown

Talent graph

The shape of Nautilus's talent

Dealroom maps Nautilus's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

9 standout operatorsDealroom-flagged across the org

3 AI specialistsincl. 3 core researchers

150 employees mappedperson by person

DimensionScore

AI Talentlive

Engineering

Product

Go-to-market

Leadership

Research

Book a demo to unlock Nautilus's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$17M patent portfolio · 19 active families

Estimated portfolio value

$17M

25.4% of market cap · 20.2× smaller than top peer Ginkgo Bioworks ($349M)

19 active patent families

Where Nautilus innovates Affinity ReagentAnalyteAssayBio moleculesBioinformatics

Where Nautilus concentrates vs peers

Each axis is a top-10 topic across Nautilus and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Nautilus

An AI-synthesized read of the highest-engagement posts about Nautilus on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Nautilus on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles